Quantitative monitoring of single nucleotide mutations by allele-specific quantitative PCR can be used for the assessment of minimal residual disease in patients with hematological malignancies throughout their clinical course.

Taira Chiaki, Matsuda Kazuyuki, Kamijyo Yuka, Sakashita Kazuo, Ishida Fumihiro, Kumagai Toshiko, Yamauchi Kazuyoshi, Okumura Nobuo, Honda Takayuki

Clinica chimica acta

Volume 412

Number 1-2

Page range 53-58

Year 2011-01

(C) 2010 Elsevier B.V.

URL http://hdl.handle.net/2241/107849

Quantitative monitoring of single nucleotide mutations by allele-specific quantitative PCR can be used for the assessment of minimal residual disease in patients with hematological malignancies throughout their clinical course

Chiaki Taira\textsuperscript{a}, Kazuyuki Matsuda\textsuperscript{a*}, Yuka Kamijyo\textsuperscript{a}, Kazuo Sakashita\textsuperscript{b}, Fumihiro Ishida\textsuperscript{c}, Toshiko Kumagai\textsuperscript{a}, Kazuyoshi Yamauchi\textsuperscript{d}, Nobuo Okumura\textsuperscript{e}, Takayuki Honda\textsuperscript{a}

\textsuperscript{a}. Department of Laboratory Medicine, Shinshu University Hospital, 3-1-1 Asahi, Matsumoto 390-8621, Japan.
\textsuperscript{b}. Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
\textsuperscript{c}. Division of Hematology, Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
\textsuperscript{d}. Department of Medicine, Molecular Clinical Pathology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan.
\textsuperscript{e}. Laboratory of Clinical Chemistry and Immunology, Department of Biomedical Laboratory Sciences, School of Health Sciences, Shinshu University, Matsumoto, Japan.

\textsuperscript{*}Correspondence: Kazuyuki Matsuda, PhD, Department of Laboratory Medicine, Shinshu University Hospital, 3-1-1, Asahi, Matsumoto, 390-8621, Japan.

TEL: +81-263-37-2802; FAX: +81-263-34-5316; E-mail: kmatsuda@shinshu-u.ac.jp

The type of paper: Original Research Communications

Running Title: AS-qPCR for monitoring MRD

Keywords: allele-specific quantitative PCR; minimal residual disease; single nucleotide mutation; hematopoietic stem cell transplantation
Abstract

**Background:** Monitoring of minimal residual disease (MRD) in patients with hematological malignancies is important for evaluating the patients’ therapeutic response and risk of relapse. Single nucleotide mutations associated with leukemogenesis can be considered as applicable MRD markers.

**Methods:** We developed an allele-specific quantitative polymerase chain reaction (AS-qPCR) for FLT3 2503G > T, KIT 2446G > T, and KIT 2447A > T and compared the change in the expression levels of the FLT3 or KIT mutations assessed by AS-qPCR to those of the RUNX1-RUNX1T1 fusion gene and WT1 by conventional quantitative PCR.

**Results:** The AS-qPCR using primers including template-mismatched nucleotide or template-mismatched nucleotide plus locked nucleic acid substituted nucleotide provided higher selectivity for mutant nucleotides. The change in the expression levels of the FLT3 or KIT mutations at the time of relapse and just after hematopoietic stem cell transplantation correlated well with that of the RUNX1-RUNX1T1 fusion gene and WT1. Moreover, during complete remission, only AS-qPCR could detect low-level expression of residual mutations.

**Conclusions:** The AS-qPCR for analyzing single nucleotide mutations contributes to the monitoring of MRD in patients without recurrent fusion gene throughout the clinical course and thus broadens the spectrum of patients in whom MRD can be monitored.
1. Introduction

In patients with hematological malignancies, minimal residual disease (MRD) status is correlated with the clinical outcome, and monitoring of MRD during chemotherapy and after hematopoietic stem cell transplantation (HSCT) is important in evaluating the patients’ therapeutic response and the risk of relapse. The targets frequently used for MRD detection are fusion gene transcripts such as RUNX1-RUNX1T1, CBFB-MYH11, and PML-RARA resulting from t(8;21)(q22;q22), inv(16)(p13q22) or t(16;16)(p13;q22), and t(15;17)(q22;q12) [1]. In addition to the recurrent reciprocal translocations associated with leukemogenesis, a number of genetic alterations such as insertion, interstitial/partial tandem duplication, and single nucleotide mutation have been reported to be involved in the pathogenesis of leukemia and associated with the prognosis of the affected patients [2,3]. Recently, several groups have performed quantitative assessment of NPM1 or FLT3 mutations and used them as MRD markers in patients with acute myelogenous leukemia [4–10]. NPM1 mutations are mainly characterized by tetrancleotide insertion. The quantitative assessments of the NPM1 mutation were performed by using TaqMan systems or LightCycler assays using primers or probes specific for the duplicated tetrancleotide. FLT3 mutations consist of 2 major types: internal tandem duplication and a missense point mutation in the tyrosine kinase domain. Quantitative assessments of FLT3-internal tandem duplication have been reported using the assay similarly to that for assessment of NPM1 mutations. According to the review by Renneville et al. [3], single nucleotide mutations of genes such as KIT, FLT3, RAS, and PTPN11; RUNX1 and CEBPA; and TP53 are involved in proliferative advantage, impairment of hematopoietic
differentiation, and regulation of cell cycle and apoptosis, respectively. These single nucleotide mutations can be considered as applicable targets for monitoring MRD. However, a few studies have reported the quantitative assessments of single nucleotide mutations as compared to those that have reported insertions/duplications. Recently, several studies have reported that single nucleotide mutations of JAK2 and MPL, or BCR-ABL were quantitatively monitored in myelofibrosis patients following transplantation [11–13], or in chronic myelogenous leukemia patients with imatinib resistance, respectively [14,15]. The detection of single nucleotide mutations in excess amount of wild-type nucleotides is more complicated than that of insertions/duplications involving several nucleotides. Allele-specific quantitative polymerase chain reaction (AS-qPCR) based on the amplification refractory mutation system (ARMS) or mismatch amplification mutation assay (MAMA) has been developed for quantification of single nucleotide mutations [16–18]. To obtain high specificity and sensitivity of the AS-qPCR, improvements, including the modification of primers and/or probes and additional procedures with restriction enzymes to digest residual wild-type nucleotides are required [19–21]. The AS-qPCR for single nucleotide mutations seems to be a useful method for the assessment of MRD.

In the present study, to evaluate whether AS-qPCR for single nucleotide mutations can be used for precise monitoring of MRD, we developed AS-qPCRs for FLT3 2503G > T, KIT 2446G > T, or KIT 2447A > T and compared the change in the expression levels of the FLT3 or KIT mutations assessed by AS-qPCR to those of RUNX1-RUNXIT1 fusion gene and WT1, which were assessed using conventional quantitative PCR (qPCR).
2. Materials and methods

2.1. Patients and controls

We performed the present study using bone marrow (BM) cells obtained from 4 t(8;21)-positive acute myeloid leukemia (AML) patients carrying gene mutations (1 with FLT3 2503G > T, 1 with KIT 2446G > T, and 2 with KIT 2447A > T) (Table 1). Ten BM samples from persons without hematological malignancies were used as normal controls. This study was approved by the institutional review board of the Shinshu University. Informed consent was obtained from the patients or guardians of the patients following institutional guidelines.

2.2 Total RNA extraction and complementary DNA (cDNA) synthesis

Total RNA was extracted from 4 t(8;21)-positive AML patients with gene mutations using the QIAamp RNA blood mini kit (QIAGEN, Valencia, CA) according to the manufacturer’s instructions. The first-strand cDNA was synthesized from 1 µg total RNA in 20 µL reaction buffer containing 10 mM of deoxynucleotide triphosphate, 0.1 M of dithiothreitol, 25 µM of random hexamer primers, and 200 U of Moloney murine leukemia virus reverse transcriptase. The reverse transcription reaction was incubated at 42°C for 1 h.

2.3. Construction of plasmids carrying wild-type or mutant FLT3 and KIT

To construct plasmids carrying the wild-type FLT3 or KIT, PCR products obtained by amplification of cDNA samples from normal controls were cloned into a pCR2.1 vector using the TA cloning kit (Invitrogen, Paisley, UK). Plasmids carrying the FLT3 2503G > T, KIT 2446G > T, or KIT 2447A > T mutation were then synthesized from the
wild-type plasmids by oligonucleotide-directed mutagenesis using a site-directed mutagenesis kit (Stratagene, La Jolla, CA). The nucleotide sequences of the wild-type and mutant plasmids were confirmed by direct sequencing from both directions on an automatic DNA sequencer (ABI3100 Genetic Analyzer, Applied Biosystems, Foster City, CA).

2.4. Design of the primers for the FLT3 or KIT mutations in 3 types of AS-qPCR

Three different mutation-specific primers for the FLT3 or KIT mutations were designed as follows: mutant AS-qPCR primers including only a mutant-matched nucleotide in the 3′-end; mismatched AS-qPCR primers including a mutant-matched nucleotide in the 3′-end and a template-mismatched nucleotide at the penultimate 3′-end; locked nucleic acid (LNA)-AS-qPCR primers including a mutant-matched nucleotide in the 3′-end, a template-mismatched nucleotide at the penultimate 3′-end, and LNA at the -2 position from the 3′-end (Table 2) [19,21].

2.5. AS-qPCR

TaqMan probes, including fluorescein amidite (FAM) at the 5′-end nucleotide and a quencher (tetramethylrhodamine, TAMRA) at the 3′-end nucleotide, were exploited to assess the specificity and sensitivity of the AS-qPCR. The AS-qPCR reaction mixture contained cDNA (corresponding to 100 ng RNA), 1× TaqMan Universal PCR Master Mix (Applied Biosystems), 0.5 μmol/L of each primer, and 0.25 μmol/L of TaqMan probe in a total of 50 μL. The AS-qPCR was performed using an ABI PRISM 7900 Sequence Detection System (Applied Biosystems) at 50°C for 2 min, 95°C for 10 min, followed by 50 cycles at 95°C for 15 sec and 60°C for 1 min. To examine the
specificity of the 3 types of AS-qPCR to discriminate between wild-type and mutant plasmid DNA, the difference of the threshold cycles ($\Delta C_t$) was calculated as follows: (Ct for mutant plasmid) - (Ct for wild-type plasmid) in each AS-qPCR assay. To investigate the sensitivity for mutant plasmid DNA of the mismatched AS-qPCR and LNA-AS-qPCR, the delay in Ct (delay Ct) was calculated as follows: (Ct for mutant plasmid in mismatched AS-qPCR or LNA-AS-qPCR) - (Ct for mutant plasmid in mutant AS-qPCR) [19,21]. The expression levels of the FLT3 or KIT mutations, RUNX1-RUNX1T1 fusion gene, or WT1 were normalized with respect to the expression of the abelson (ABL) gene, and expressed as copy numbers every $10^4$ copies of ABL [22]. Each AS-qPCR assay for an individual patient was performed in triplicate.

2.6. Detection limit of the AS-qPCR for FLT3 and KIT mutations or qPCR for RUNX1-RUNX1T1 fusion gene, and normal expression level of WT1

To determine the detection limit of the AS-qPCR, cDNA obtained from patients at diagnosis were serially 10-fold diluted in pooled cDNA from healthy controls, and the AS-qPCR was performed using the diluted samples [23]. In patient 2, the sample at diagnosis was not available and thus, the BM sample after chemotherapy was used to determine the detection limit. The normal expression level of WT1 was determined using BM samples from persons without hematological malignancies.

2.7. Quantification of RUNX1-RUNX1T1 fusion gene and WT1

The expression levels of the RUNX1-RUNX1T1 fusion gene or WT1 were quantified by conventional qPCR using the cDNA of the same time point as that used for the AS-qPCR [1,24].
2.8. Statistics

Analysis of variance (ANOVA) was used for the comparisons of ΔCt among the 3 types of AS-qPCR, and unpaired t-test was used for the comparisons of delay Ct between mismatched AS-qPCR and LNA-AS-qPCR; $p < 0.05$ was considered to be significant.

3. Results

3.1. Characterization of mutant AS-qPCR, mismatched AS-qPCR, and LNA-AS-qPCR

Using equal copy numbers of the constructed wild-type and mutant plasmids, the ΔCt was examined in the mutant AS-qPCR, mismatched AS-qPCR, and LNA-AS-qPCR (Figure 1). Compared with the mutant AS-qPCR, the other 2 types of AS-qPCR (mismatched AS-qPCR and LNA-AS-qPCR) showed significantly higher specificity for discrimination between the wild-type and mutant plasmid in all 3 gene mutations (Fig. 1, $p < 0.01$). Next, the delay Ct was calculated to evaluate the sensitivity for mutant plasmids by mismatched AS-qPCR or LNA-AS-qPCR (Fig. 1). The delay Ct in the mismatched AS-qPCR for $FLT3$ 2503G $\rightarrow$ T, $KIT$ 2446G $\rightarrow$ T, and $KIT$ 2447A $\rightarrow$ T were 0.12, 0.00, and 0.69 cycles, respectively. The delay Ct in the LNA-AS-qPCR for $FLT3$ 2503G $\rightarrow$ T, $KIT$ 2446G $\rightarrow$ T, and $KIT$ 2447A $\rightarrow$ T were 1.59, 0.17, and 4.63 cycles, respectively. We adopted the LNA-AS-qPCR for $FLT3$ 2503G $\rightarrow$ T and $KIT$ 2446G $\rightarrow$ T except $KIT$ 2447A $\rightarrow$ T. For $KIT$ 2447A $\rightarrow$ T, we adopted the mismatched AS-qPCR because the delay Ct in the LNA-AS-qPCR was 4.63 cycles which meant a more than 10 ($2^{3.33}$)-fold reduction of sensitivity.
3.2. Detection limit of the AS-qPCR for FLT3 and KIT mutations or qPCR for the RUNX1-RUNX1T1 fusion gene, and normal expression level of WT1

The expression levels of FLT3 2503G > T or KIT 2447A > T at diagnosis in patient 1, 3, and 4 were $2.04 \times 10^4$, $3.02 \times 10^4$, and $4.43 \times 10^4$, respectively (Fig. 2a, c, and d). The detection limits of FLT3 2503G > T or KIT 2447A > T in patient 1, 3, and 4 were $2.04 \times 10$, $3.02 \times 10$, and $4.43 \times 10$, respectively (Fig. 2a, c, and d). As compared with the expression level at diagnosis, the mutations could be detected at a $10^3$-fold lower expression level. In patient 2 (Fig. 2b), a sample at diagnosis was not available; therefore, a BM sample after chemotherapy was used to determine the detection limit. The expression level of KIT 2446G > T in the BM sample after chemotherapy was $3.85 \times 10^3$ and the detection limit was $3.85 \times 10$; thus, the mutation could be detected at a $10^2$-fold lower expression level. The expression levels of the RUNX1-RUNX1T1 fusion gene in patient 1, 2, 3, and 4 were $3.75 \times 10^4$, $3.03 \times 10^2$, $2.02 \times 10^4$, and $2.71 \times 10^4$, respectively (Fig. 2). The detection limits in patient 1, 2, 3, and 4 were $3.75$, $3.03$, $2.02$, and $2.71$, respectively (Fig. 2). As compared with the expression level at diagnosis, the RUNX1-RUNX1T1 fusion gene could be detected at a $10^4$-fold lower expression level, except in patient 2. In patient 2, the RUNX1-RUNX1T1 fusion gene could be detected at a $10^2$-fold lower expression level. The expression levels of WT1 in patient 1, 2, 3, and 4 were $1.59 \times 10^3$, $3.03 \times 10$, $3.39 \times 10^2$, and $3.90 \times 10^3$, respectively (Fig. 2). The mean expression level of WT1 in 10 normal controls was $(5.96 \pm 4.63) \times 10$ (Fig. 2).

3.3 Comparison of the change in the expression levels of FLT3 2503G > T, KIT
2446G > T, or KIT 2447A > T assessed by AS-qPCR with that of the RUNX1-RUNX1T1 fusion gene and WT1 by qPCR

Using samples obtained from 4 t(8;21)-positive patients with FLT3 2503G > T, KIT 2446G > T, or KIT 2447A > T, the clinical significance of the AS-qPCR was investigated by comparison of the change in the expression level of these mutations with that of the RUNX1-RUNX1T1 fusion gene and WT1. In patient 1 (Fig. 2a), the expression level of FLT3 2503G > T and the RUNX1-RUNX1T1 fusion gene decreased to an undetectable level soon after induction therapy and retained this level during complete remission (CR). In contrast, the expression level of WT1 did not show more than 10²-fold reduction after induction therapy and the levels did not further decline during CR. In patient 2 (Fig. 2b) whose diagnostic sample was not available and a sample obtained after chemotherapy was used as the first time point of the follow-up, the expression level of KIT 2446G > T showed an increase before and at the time of relapse, which was in accordance with that of the RUNX1-RUNX1T1 fusion gene and WT1. In the follow-up during continuous CR after HSCT, the expression levels of KIT 2446G > T and the RUNX1-RUNX1T1 fusion gene were detected at the level of 10- and 10³-fold reduction. The expression level of WT1 maintained at steady levels close to that of normal controls. In patient 3 (Fig. 2c) who underwent HSCT twice, the increase in the expression level of KIT 2447A > T at the time of the first and second relapse, and the decrease in the expression level following the first and second HSCT agreed well with the change in the expression levels of the RUNX1-RUNX1T1 fusion gene and WT1. During CR following the first HSCT, the expression levels of KIT 2447A > T were marginally detectable, while that of the RUNX1-RUNX1T1 fusion gene were below the detection limit. Seven months after the second HSCT, the expression
level of *KIT* 2447A > T was below the detection limit and retained at that level until now. In patient 4 (Fig. 2d), after HSCT, the expression levels of *KIT* 2447A > T and the RUNX1-RUNXIT1 fusion gene decreased 10³-fold and that of WT1 decreased 40-fold. However, the expression of both *KIT* 2447A > T and the *RUNX1-RUNXIT1* fusion gene have been detected at the level of 10 to 10² at 11 months after HSCT.

4. Discussion

In the present study, we developed AS-qPCRs to quantify leukemia-associated single nucleotide mutations in genes such as *FLT3* and *KIT*, and evaluated the AS-qPCR to monitor MRD during chemotherapy and post-HSCT by comparison with the qPCR for the *RUNX1-RUNXIT1* fusion gene and WT1.

Several allele-specific PCR methods based on ARMS or MAMA have been developed for the detection of single nucleotide mutations [16,17]. The primers included a mutant-matched nucleotide at the 3′-end and a template-mismatched nucleotide near the 3′-end. Subsequently, an AS-qPCR based on ARMS or MAMA was developed to quantify low levels of mutant nucleotides in the presence of high levels of the counterpart wild-type nucleotides [18]. To increase the selectivity of the AS-qPCR, our present methods utilized primers including template-mismatched nucleotides or template-mismatched nucleotides plus LNA-substituted nucleotides which increased the binding affinity compared to standard nucleotides [19,21,25–27]. For all mutations evaluated in this study, the ΔCt in the LNA-AS-qPCR was more than 15 cycles and that in the mismatched AS-qPCR was more than 9 cycles (Fig. 1). The LNA-AS-qPCR provided the highest selectivity for the 3 mutations. The LNA-AS-qPCR was used to monitor the *FLT3* 2503G > T and *KIT* 2446G > T
mutations, and the mismatched AS-qPCR was used to monitor the KIT 2447A > T mutation. Accordingly, we developed adequate AS-qPCRs with high specificity and sensitivity for each mutation.

Throughout the clinical course, monitoring of MRD in patients with hematological malignancies is important for the early detection of hematological and/or extramedullary relapse. Quantitative assessments of MRD can be achieved by qPCR techniques which target immunoglobulin/T-cell receptor gene rearrangements and fusion gene transcripts and by fluorescence in situ hybridization techniques which analyze for numerical and constructional chromosome abnormalities. For the purpose of clinical validation, the present AS-qPCR assay was used for monitoring of MRD in 4 patients of whom sequential samples were available.

The qPCR analyses for fusion genes have been widely used and are regarded as reliable methods to evaluate MRD. In comparison between the present AS-qPCR and qPCR for fusion genes, we used RUNX1-RUNX1T1 as an adequate MRD marker because the KIT or FLT3 mutations have been detected frequently in patients with the RUNX1-RUNX1T1 fusion gene. Out of the 4 patients with the RUNX1-RUNX1T1 fusion gene available for screening of the gene mutations, 1 had the FLT3 mutation and 3 patients had KIT mutations. The RUNX1-RUNX1T1 fusion transcripts are detected persistently by non-quantitative PCR analysis, so that the quantitative analysis of fusion gene transcripts should be performed to evaluate MRD [28,29]. At relapse, the increases in the expression of the FLT3 or KIT mutant gene by AS-qPCR were in accordance with that of the RUNX1-RUNX1T1 fusion gene by qPCR (Fig. 2a and b). In some measurements during complete remission (CR) in patient 3, the expression of KIT 2447A > T was detected at quantifiable levels, while that of the RUNX1-RUNX1T1
fusion gene was below the detection limit (Fig. 2c). The recent studies have shown that, in patients with t(8;21)-positive leukemia, the expression of both wild-type KIT and mutated KIT was significantly higher than that in patients with t(8;21)-negative leukemia [30,31]. Therefore, during CR in patient 3, the over-expressed mutated KIT gene could be detected by the present AS-qPCR. The observation that patient 3 experienced a second relapse indicates that the AS-qPCR may be useful to monitor MRD for prediction of imminent relapse in patients with only a single nucleotide mutation as available MRD marker. In patient 4, although no clinical and hematological abnormalities have been observed after HSCT, both KIT 2447A>T and RUNXI-RUVXIT1 have been detected at quantifiable levels persistently, and there is a possibility of relapse at high risk (Fig. 2d). Therefore, close follow up of patient 4 with AS-qPCR is requisite. To develop a single gene mutation as a MRD marker, the stability of the gene mutation itself during follow-up is needed to be validated.

WT1 transcripts have been reported as MRD marker in patients with no recurrent chromosomal or genetic abnormalities. There have been controversies regarding the significance of WT1 transcripts as MRD marker, because WT1 transcripts were detected not only in tumor cells but also in normal cells [32,33]. RUNXI-RUXIT1-positive patients showed significantly lower WT1 expression than patients with other types of AML and normal individuals [34,35]. In the present cases with the RUNXI-RUXIT1 fusion gene, the ABL-normalized WT1 expressions levels were in the range $10^2$–$10^4$. Although no decreases in the WT1 expression of more than $10^2$-fold were observed during CR, increases in the WT1 expression at relapse were paralleled to that of KIT 2446G > T or KIT 2447A > T and the RUNXI-RUXIT1 fusion gene (Fig. 2b and c). A quality-controlled standardized approach has been developed for an accurate and
reproducible quantification of WT1 expression [36]. For the wide application of the present AS-qPCR to monitor MRD in patients without recurrent chromosomal and genetic abnormalities, it should be required to compare the alteration in the quantity of the mutant gene to that of WT1 in a large number of patients.

The percentage of autologous cells (chimerism) analyzed by short tandem repeat-PCR (STR-PCR), which characterizes the origin of post-transplant hematopoiesis, has been used as a surrogate marker for MRD [37]. The change in the quantity of the mutation detected by AS-qPCR using genomic DNA corresponded with the change of chimerism by STR-PCR [21]. The AS-qPCR was more sensitive than the STR-PCR. In our patients, the mutated gene could be quantified significantly by AS-qPCR even when the chimerism by STR-PCR was less than 5% or negative (data not shown).

In conclusion, the AS-qPCRs for single nucleotide mutations had comparable accuracy to qPCR for the RUNX1-RUNXIT1 fusion gene and WT1 and were applicable to monitor MRD throughout the clinical course including prior to transplantation and post-transplantation. The AS-qPCR for single nucleotide mutations may permit us to monitor MRD in patients that lack recurrent chromosomal abnormalities and the specific fusion gene, which broadens the spectrum of patients in whom MRD can be monitored.

**Abbreviations:** MRD, minimal residual disease; AS-qPCR, allele-specific quantitative polymerase chain reaction; HSCT, hematopoietic stem cell transplantation; ARMS, amplification refractory mutation system; MAMA, mismatch amplification mutation assay; AML, acute myeloid leukemia; LNA, locked nucleic acid; FAM, fluorescein amidite; TAMRA, tetramethylrhodamine; ABL, abelson; CR, complete remission.
References


Nonstandard abbreviations: AS-qPCR, allele specific-quantitative PCR; q-PCR, quantitative PCR; LNA, locked nucleic acid; ARMS, amplification refractory mutation system; MAMA, mismatch amplification mutation assay; STR-PCR, short-tandem repeat PCR; BM, bone marrow;
Figure Legends

Figure 1. Comparison of 3 types of AS-qPCRs

Three types of AS-qPCRs (1, mutant AS-qPCR; 2, mismatched AS-qPCR; 3, LNA-AS-qPCR) were compared in terms of difference of threshold cycles (ΔCt) and delay in Ct (delay Ct). The ΔCt was calculated as follows: (Ct for mutant plasmid) - (Ct for wild-type plasmid) in each AS-qPCR assay. The delay Ct was calculated as follows: (Ct for mutant plasmid in mismatched AS-qPCR or LNA-AS-qPCR) - (Ct for mutant plasmid in mutant AS-qPCR). Data are expressed as means ± S.D. *, p < 0.05; **, p < 0.01 in comparisons of ΔCt among the 3 types of AS-qPCRs. ##, p < 0.01 in comparisons of delay Ct between mismatched AS-qPCR and LNA-AS-qPCR. N.S., not significant.

Figure 2. Comparison of the quantity of FLT3 2503G > T, KIT 2446G > T, and KIT 2447A > T transcripts by AS-qPCR with that of RUNX1-RUNXIT1 fusion and WT1 transcripts by qPCR throughout the clinical course

The expression of the mutated genes, the RUNX1-RUNXIT1 fusion gene, and the WT1 gene was evaluated in 4 patients. The expression of the target genes using cDNA was normalized with respect to the expression of the abelson (ABL) gene, and expressed as copy numbers every $10^4$ copies of ABL. To determine the detection limit of the AS-qPCRs for FLT3 2503G > T, KIT 2446G > T, and KIT 2447A > T, and that of the qPCR for the RUNX1-RUNXIT1 fusion gene, cDNA obtained from patients at diagnosis were serially 10-fold diluted in pooled cDNA from healthy controls and the AS-qPCR and qPCR were performed using the diluted samples. Dotted lines in FLT3 2503G > T,
KIT 2446G > T, KIT 2447A > T, and RUNX1-RUNXIT1 indicate the detection limit of
the AS-qPCRs. The normal expression of the WT1 gene was determined using 10 BM
samples from persons without hematological malignancies. Dotted line in WT1
indicates the mean expression level of normal controls. CR, complete remission; R,
relapse; HSCT, hematopoietic stem cell transplantation
Table 1. Summary of the 4 patients

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age</th>
<th>Diagnosis</th>
<th>Type of gene mutation</th>
<th>Karyotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>5</td>
<td>AML (M2)</td>
<td>FLT3 2503G &gt; T</td>
<td>46,XX,t(8;21)(q22;q22)[6]/46,XX[5]</td>
</tr>
<tr>
<td>2</td>
<td>8</td>
<td>AML (M2)</td>
<td>KIT 2446G &gt; T</td>
<td>45,X,-Y,t(8;21)(q22;q22)[20]</td>
</tr>
<tr>
<td>3</td>
<td>2</td>
<td>AML (M2)</td>
<td>KIT 2447A &gt; T</td>
<td>46,XY,der(4)t(4:8)(p16;q21),der(8)t(8;21)(q22;q22)[12]/46,XY[7]</td>
</tr>
<tr>
<td>4</td>
<td>27</td>
<td>AML (M2)</td>
<td>KIT 2447A &gt; T</td>
<td>46,XX,t(8;21)(q22;q22)[20]</td>
</tr>
<tr>
<td>Target genes</td>
<td>Primers (5′ - 3′)</td>
<td>Probes (5′ - 3′)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------</td>
<td>-----------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>FLT3</em> 2503G &gt; T</td>
<td>F: gatatgtgacatttggtggatggtGcG*&lt;br&gt;R: gtgtgatgtgctttcaacagge</td>
<td>FAM-gcaatgcctgtcgctgtaaatgtggatg-TAMRA</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>KIT</em> 2446G &gt; T</td>
<td>F: gatttgtgattttgcttagccagCgt&lt;br&gt;R: ccatagcaggacgctacatttc</td>
<td>FAM-ccatccacttcaggtcagctggt-TAMRA</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>KIT</em> 2447A &gt; T</td>
<td>F: gatttgtgattttgcttagccagact&lt;br&gt;R: ccatagcaggacgctactttc</td>
<td>FAM-ccatccacttcaggtcagctggt-TAMRA</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>RUNX1-RUNX1T1</em></td>
<td>F: cacctaccacagccatcaaa&lt;br&gt;R: atccacaggtgctggtat</td>
<td>FAM-aacctgaaatcgtactgagaagcactca-TAMRA</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>WT1</em></td>
<td>F: cagctgtgataagatattttaagg&lt;br&gt;R: gaagtccacagtgtggttgtttcga</td>
<td>FAM-cttagagatgtcagcagagaagacactg-TAMRA</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>ABL (abelson)</em></td>
<td>F: tggagataactctaagcatataaaggt&lt;br&gt;R: gatgtgtgtcggaccca</td>
<td>FAM-ccattttggtggtgtcagccact-TAMRA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* The LNA base is depicted in uppercase; template-mismatched base in lowercase in italics; mutant-matched base specific base in lowercase underlined. LNA, locked nucleic acid; FAM, fluorescein amidite; TAMRA, tetramethylrhodamine. The primers and probes for *RUNX1-RUNX1T1*, *WT1*, and *ABL* were designed according to the previous reports [1,22,24].

Table 2. Sequences of primers and probes for AS-qPCR
Figure 1

(a) FLT3 2503G > T

(b) KIT 2446G > T

(c) KIT 2447A > T

Fig 1.
Figure 2

(a) Patient No.1  (b) Patient No.2  (c) Patient No.3  (d) Patient No.4

Relative value (Target/ABL×10^4)

<table>
<thead>
<tr>
<th></th>
<th>Months after diagnosis</th>
<th>Months after diagnosis</th>
<th>Months after diagnosis</th>
<th>Months after diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLT3 2503G &gt; T</td>
<td>10^5</td>
<td>10^5</td>
<td>10^5</td>
<td>10^5</td>
</tr>
<tr>
<td>RUNX1-RUNXIT1</td>
<td>10^5</td>
<td>10^5</td>
<td>10^5</td>
<td>10^5</td>
</tr>
<tr>
<td>WT1</td>
<td>10^3</td>
<td>10^3</td>
<td>10^3</td>
<td>10^3</td>
</tr>
<tr>
<td>KIT 2446G &gt; T</td>
<td>10^5</td>
<td>10^5</td>
<td>10^5</td>
<td>10^5</td>
</tr>
<tr>
<td>RUNX1-RUNXIT1</td>
<td>10^5</td>
<td>10^5</td>
<td>10^5</td>
<td>10^5</td>
</tr>
<tr>
<td>WT1</td>
<td>10^3</td>
<td>10^3</td>
<td>10^3</td>
<td>10^3</td>
</tr>
<tr>
<td>KIT 2447A &gt; T</td>
<td>10^5</td>
<td>10^5</td>
<td>10^5</td>
<td>10^5</td>
</tr>
<tr>
<td>RUNX1-RUNXIT1</td>
<td>10^5</td>
<td>10^5</td>
<td>10^5</td>
<td>10^5</td>
</tr>
<tr>
<td>WT1</td>
<td>10^3</td>
<td>10^3</td>
<td>10^3</td>
<td>10^3</td>
</tr>
</tbody>
</table>

Fig2.